John Markman, MD, on Subcutaneous Tanezumab vs Tramadol or Placebo for Chronic Low Back Pain

In this podcast, Dr Markman discusses promising findings from a large phase 3 trial comparing subcutaneous tanezumab, a monoclonal antibody with a novel mechanism of action, vs tramadol and placebo among patients with chronic low back pain and history of inadequate response or intolerance to standard-of-care analgesics. Read the transcript here. This study was featured in the 2020 American Academy of Neurology Science Highlights.

Discover more insights from your peers in our Pain Medicine Excellence Forum.

John Markman, MD, is a professor in the Department of Neurosurgery and Neurology and director of the Translational Pain Research Program in the Neuromedicine Pain Management Division at the University of Rochester Medical Center in Rochester, New York.

Disclosures: Dr Markman has served on an advisory board for Clexio Biosciences, Flexion Therapeutics, Quark Pharmaceuticals, Quartet Medicine, Collegium Pharmaceutical, Purdue Pharma, Biogen, Novartis, Aptinyx, Nektar, Greenwich Bioscience, Allergan, Grünenthal, Eli Lilly and Company, Depomed, Janssen Pharmaceuticals, Teva Pharmaceutical Industries, KemPharm, Abbott Laboratories, Plasma Surgical, Chromocell, Convergence Pharmaceuticals, Inspirion, Pfizer, Sanofi, Daiichi Sankyo, Greenwich Bioscience, SK Lifescience, and Trevena; has served as a consultant to Trigemina, Editas Medicine, and Plasma Surgical; has equity in YellowBlack Corp; and has served on data safety monitoring boards for Novartis and Allergan.

References:

• Markman J, Bolash R, McAlindon T, et al. Subcutaneous tanezumab versus tramadol for chronic low back pain: efficacy and safety results from a 56-week phase 3 study with a 24-week follow up period (306). Neurology. 2020;94(15 suppl.). https://n.neurology.org/content/94/15_Supplement/306
• Markman J, Bolash R, McAlindon T, et al. Subcutaneous tanezumab versus tramadol in patients with chronic low back pain: 16-week efficacy and safety results from a phase 3 study (305). Neurology. 2020;94(15 suppl.). https://n.neurology.org/content/94/15_Supplement/305
• Markman D, Bolash R, McAlindon T, et al. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. Pain. Published online May 19, 2020. https://journals.lww.com/pain/Abstract/9000/Tanezumab_for_chronic_low_back_pain__a_randomized,.98400.aspx